Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy

Agbulut, Onnik; Menot, Marie-Laurence; Li, Zhenlin; Marotte, F.; Paulin, Denise; Hagège, Albert; Chomienne, Christine; Samuel, Jane‐Lise; Menasché, Philippe

doi:10.1016/s0008-6363(03)00281-5

Cited by 63 publications

(54 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…They concluded that the functional benefits were questionable because only a very small number of cells had transdifferentiated. 17 In the present study, however, we demonstrated improved LV function and engrafted GFP-positive tissue in the LV wall. Among the GFP-positive cells, we also found donor cell-derived -sarcomeric actin-positive tissue.…”

Section: Discussioncontrasting

confidence: 43%

“…In addition, although there are a number of reports of BMC transplantation to ischemic hearts, only a little is known about the process in nonischemic dilated cardiomyopathy (DCM). [14][15][16][17] Therefore, the purpose of this study was to compare the efficacy of BMC transplantation among various routes of cell delivery, and thereby elucidate how BMCs should be transplanted, using mouse models of acute and old myocardial infarction (AMI and OMI) and DCM.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Delivery Route in Bone Marrow Cell Transplantation Should be Optimized According to the Etiology of Heart Disease

Nakajima

Sakakibara

Tambara

et al. 2008

Circ J

View full text Add to dashboard Cite

Preparation of BMCsBMCs were harvested from 8-week-old syngenic and transgenic male C57Bl/6 mice expressing enhanced green fluorescent protein (GFP), by flushing the femurs and tibias Circ J 2008; 72: 1528 -1535 (Received August 23, 2006 revised manuscript received April 28, 2008; accepted May 9, 2008 Background Recent studies have revealed that bone marrow cell (BMC) transplantation is effective not only for myocardial infarction (MI), but also for dilated cardiomyopathy (DCM). However, the method of administering donor cells remains unknown, and may differ between MI and DCM. In the present study, intramyocardial (IM) injection and intravenous (IV) delivery of BMC were compared in each etiological model. Methods and Results MI was induced in 72 mice and DCM in another 36 mice by doxorubicin. BMCs were administered IV or IM in an acute MI (AMI), old MI (OMI) or DCM model. In the AMI model, left ventricular (LV) remodeling was reduced in both the IM-and IV-groups, but only in the IM-group in the OMI model. In the DCM model, the LV dimension of the IV-group was smaller than that of the IM-group. Histological examination showed that green fluorescent protein (GFP) cells were equally distributed in the infarct area of the IV-and IMgroups in AMI, and in the IM-group in the OMI model. In the DCM model, GFP cells were diffusely scattered throughout the ventricular wall in the IV-group, but were confined to the injection site in the IM-group. Conclusions In OMI, IM delivery of BMCs was more effective than IV; however, IV delivery was superior in DCM. Delivery route should be selected according to the etiology of heart disease to optimize the efficacy of BMC transplantation. (Circ J 2008; 72: 1528 -1535

show abstract

Section: Discussioncontrasting

confidence: 43%

mentioning

confidence: 99%

Delivery Route in Bone Marrow Cell Transplantation Should be Optimized According to the Etiology of Heart Disease

Nakajima

Sakakibara

Tambara

et al. 2008

Circ J

View full text Add to dashboard Cite

show abstract

“…This may account for the observation that patients with non-ischemic cardiomyopathy may have higher levels of CD34 + EPCs in peripheral blood, as in the absence of cardiac homing signals these cells fail to migrate and incorporate into the myocardium to assist with endogenous repair. Preclinical data in non-ischemic cardiomyopathy has focused on small animal models of toxic (doxorubicin-induced) or genetic cardiomyopathy, with promising results demonstrated for both SkMs and BM-derived cells (Agbulut et al 2003;Kondoh et al 2007;Ohnishi et al 2007). Recently, myoblast transplantation also achieved functional benefi t in an ovine model of cardiomyopathy, induced by intracoronary doxorubicin (Borenstein et al 2007).…”

Section: Non-ischemic Cardiomyopathymentioning

confidence: 99%

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Psaltis

Gronthos

Worthley

et al. 2008

Clinical medicine. Cardiology

View full text Add to dashboard Cite

“…Subsequent studies revealed that fusion events between marrowderived cells and cardiomyocytes was the likely source of these transdifferentiation events (Alvarez-Dolado et al 2003). Other studies have suggested that hematopoietic stem cells were cardiomyogenic following direct transplantation (Orlic et al 2001a) or cytokine-mediated mobilization (Orlic et al 2001b) into the infarcted myocardium, although these experiments have not readily been replicated by other groups (Agbulut et al 2003;Balsam et al 2004;Murry et al 2004;Nygren et al 2004). The basis for these differential results was not clear, but likely reflected differences in the approaches used to isolate the stem cell population and/ or differences in the experimental read-out used to document cardiomyogenic differentiation.…”

Section: Adult-derived Stem Cellsmentioning

confidence: 99%

Cardiac Repair by Embryonic Stem-Derived Cells

Rubart

Field

2006

Stem Cells

View full text Add to dashboard Cite

Cell transplantation approaches offer the potential to promote regenerative growth of diseased hearts. It is well established that donor cardiomyocytes stably engraft into recipient hearts when injected directly into the myocardial wall. Moreover, the transplanted donor cardiomyocytes participate in a functional syncytium with the host myocardium. Thus, transplantation of donor cardiomyocytes resulted in at least partial restoration of lost muscle mass. It is also well established that embryonic stem (ES) cells differentiate into cells of ecto-, endo-, and mesodermal lineages when cultured under appropriate conditions in vitro. Robust cardiomyogenic differentiation was frequently observed in spontaneously differentiating ES cultures. Cellular, molecular and physiologic analyses indicated that ES-derived cells were bona fide cardiomyocytes, with in vitro characteristics typical for cells obtained from early stages of cardiac development. Thus, ES-derived cardiomyocytes constitute a viable source of donor cells for cell transplantation therapies.

show abstract

Temporal patterns of bone marrow cell differentiation following transplantation in doxorubicin-induced cardiomyopathy

Cited by 63 publications

References 37 publications

Delivery Route in Bone Marrow Cell Transplantation Should be Optimized According to the Etiology of Heart Disease

Delivery Route in Bone Marrow Cell Transplantation Should be Optimized According to the Etiology of Heart Disease

Cellular Therapy for Cardiovascular Disease Part 2—Delivery of Cells and Clinical Experience

Cardiac Repair by Embryonic Stem-Derived Cells

Contact Info

Product

Resources

About